Drug General Information (ID: DDI2GMH9WJ)
Drug Name			Aprotinin		Drug Info		Factor IX Complex (Human)		Drug Info
Drug Type		Small molecule				Protein/peptide
Therapeutic Class		Serine Protease Inhibitor				Coagulation Modifiers

Mechanism of Aprotinin-Factor IX Complex (Human) Interaction (Severity Level: Major)
Additive thrombogenic effects Click to Show/Hide Mechanism Graph
Drug Name		Aprotinin				Factor IX Complex (Human)
Mechanism		Thrombogenic effects				Thrombogenic effects
Key Mechanism Factor 1
		Factor Name		Thrombogenic effects
		Factor Description		Drug-induced thrombosis disrupts the balance between thrombogenic factors and protective mechanisms and tends to produce thrombosis. Drug-induced thrombosis usually causes venous thrombotic events, and arterial thrombotic events are also noted as a result of drug administration
Mechanism Description		Additive thrombogenic effects by the combination of Aprotinin and Factor IX Complex (Human)

Recommended Action
Management		Concomitant administration of antifibrinolytic agents with other hemostatic agents should generally be avoided. Consult the manufacturer's product labeling for recommended dosing intervals between products.

References
1	Product Information. LYSTEDA (tranexamic acid). Xanodyne Pharmaceuticals Inc, Newport, KY.
2	Product Information. Cyklokapron (tranexamic acid). Pharmacia and Upjohn, Kalamazoo, MI.
3	Product Information. Amicar (aminocaproic acid). Immunex Corporation, Seattle, WA.